Contents
On this page
- Editorial scope of the target journal
- Relevance of publication trends in generic drug research
- ICMJE authorship criteria
- Role and functions of COPE
- The GaBI Journal as a second specialty venue
- Identification of predatory and low-quality journals
- Disclosure of conflicts of interest
- Editorial responses to suspected ghost or guest authorship
- Pre-submission synthesis
Academy · Research Publication · Generic Medicines Journal Selection
Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics
Beyond indexing, the selection of a journal for generic medicines research requires matching the manuscript to the journal’s stated editorial scope and meeting the authorship and ethics standards that reputable journals now expect.
Generic medicines research spans regulatory policy, market economics, pharmacology and clinical substitution practice, so a single manuscript may plausibly suit several journals with very different scopes. Selection of an unsuitable journal prolongs the review process; selection of a suitable one requires matching the content of the paper to the journal’s stated aims and ensuring that the manuscript meets the authorship and ethics standards that editors now assess before review.
Learning objectives
- The definition of scope in a specialty journal such as the Journal of Generic Medicines
- The relevance of bibliometric trends in generic drug publishing to journal selection
- The full requirements of the four ICMJE authorship criteria
- The role of COPE and the reasons its name and role are often misstated
Common misconceptions
- “Generic medicines constitute a single topic, so any journal that uses the phrase is interchangeable.” The Journal of Generic Medicines describes itself as an international business journal for the generic medicines sector, with a stated scope covering business development, regulatory affairs, manufacturing and marketing of generic pharmaceuticals; a clinical pharmacokinetics paper and a market-access policy paper are therefore not equally suitable for it.
- “Authorship requires only some contribution to the research, and ethics bodies are interchangeable regulators.” ICMJE (the International Committee of Medical Journal Editors) sets out four specific, cumulative authorship criteria, and COPE (the Committee on Publication Ethics), rather than an informal “ethics committee”, is the organisation on which most journals rely for publication-ethics guidance, case discussion and misconduct review procedures. An incorrect name or role weakens the ethics and authorship statement of a manuscript.
Editorial scope of the target journal
The Journal of Generic Medicines, published by SAGE, describes itself as the major international business journal for professionals in the generic medicines sector, aimed at practitioners rather than purely academic audiences. Its stated coverage spans business development, regulatory affairs (including legal and regulatory updates), manufacturing, and marketing of generic pharmaceuticals 1. Recent published topics have included complex generics, clinical trial regulation, AI and Industry 4.0 applications in pharmaceutical manufacturing, clinician perceptions of generic medicines, excipient differences between generic formulations, and regulation of nanoparticle and liposomal generic products 1.
This scope determines manuscript fit: a paper reporting a clinical bioequivalence trial, a health-economic analysis of generic uptake, and a regulatory-policy commentary on biosimilar approval pathways all constitute “generic medicines” research in a broad sense, but they are not equally well matched to the editorial priorities and reviewer expertise of the same specialty journal.
Relevance of publication trends in generic drug research
Bibliometric analysis of the broader generic-drug literature provides a useful check on where a manuscript is likely to be well received. A 2016 study in Clinical Therapeutics, “Patterns and trends in scientific research on generic drugs,” examined how publication volume and topic focus in this field have evolved, documenting how the generic-drugs literature as a whole has grown and diversified 2. Identifying where similar recent papers on the specific sub-topic (regulatory, clinical or economic) have been published is a more reliable guide than assuming that any journal with “generic” in its scope will be suitable.
The adjacent biosimilars literature shows the same pattern more distinctly. A 2018 bibliometric analysis in the Journal of Pharmaceutical Policy and Practice identified 2,330 biosimilar-related documents in Scopus between 2004 and 2016, with annual output increasing from 3 papers in 2004 to 521 in 2016, and found that research terminology shifted over that period from broad topics such as legislation and molecular structure toward specific diseases and named products 9. A manuscript on, for example, biosimilar interchangeability for a specific indication enters a literature that has already moved beyond generic, structure-focused framing; this is a further reason to consult recent comparable papers rather than rely on the title of a journal alone.
ICMJE authorship criteria
The International Committee of Medical Journal Editors (ICMJE), whose name should be cited exactly, sets out four criteria, all of which must be met for an individual to be listed as an author of a manuscript:
- Substantial contributions to the conception or design of the work, or to the acquisition, analysis, or interpretation of data for the work;
- Drafting the work or critically revising it for important intellectual content;
- Final approval of the version to be published; and
- Agreement to be accountable for all aspects of the work, including ensuring that questions related to its accuracy or integrity are appropriately investigated and resolved 3.
For generic-medicines manuscripts with multiple contributing teams (a clinical site, a statistical analysis group, a sponsor’s regulatory affairs staff), this standard is where authorship disputes most often arise. Confirmation that each listed author meets all four criteria before submission, rather than after a reviewer or editor raises the question, avoids delays. The World Association of Medical Editors (WAME), a sister organization to ICMJE in medical editing, applies the same four-part test in its most recent guidance on a very different problem: its recommendations on chatbots and generative AI state that an AI tool cannot be listed as an author, in part because it cannot give final approval of the version to be published or take responsibility for the accuracy of the work. This is an application of the ICMJE criteria described in this section to a case about which authors increasingly enquire 10.
Role and functions of COPE
COPE, the Committee on Publication Ethics, is a forum founded in 1997 by medical journal editors concerned about publication misconduct; it is now a registered charity and limited company 4. Its core function for member journals is to provide a venue — a quarterly Forum and a searchable case database — where anonymized ethics cases can be discussed and benchmarked against precedent, alongside confidential advice between meetings and published guidance on best practice for editors 4. When a complaint is raised, COPE does not itself adjudicate the underlying scientific allegation; it assesses whether the journal followed its own code of conduct and best-practice procedures 4.
Many journals in the generic-medicines and broader pharmaceutical field are COPE members and will expect the ethics statement of a submission to cite COPE guidance accurately; an incorrect full name or remit is a minor but noticeable indication of a hurried submission.
The GaBI Journal as a second specialty venue
The Journal of Generic Medicines is not the only dedicated outlet. The Generics and Biosimilars Initiative Journal (GaBI Journal), published quarterly since 2012 by Pro Pharma Communications International, states a scope covering "all aspects of generic and biosimilar medicines," from fundamental research through clinical application to policy, and explicitly welcomes research reports, literature reviews, case studies and evidence-based commentaries 5. Its stated editorial topics — formulation development, manufacturing, in vivo and in vitro equivalence testing, regulatory issues, supply-chain management and pharmacoeconomics — overlap with, but are not identical to, the Journal of Generic Medicines' more business-and-regulatory-first framing 5. A manuscript centred on equivalence testing methodology or biosimilar-specific pharmacoeconomics may therefore be better suited to GaBI Journal than to a journal whose stated priority is commercial and regulatory strategy, even though both titles use “generic medicines” in their self-description.
Identification of predatory and low-quality journals
Generic-medicines research lies at the intersection of pharmacology, regulatory affairs and health economics, which also makes it a target for lower-quality or predatory journals that seek cross-disciplinary submissions by promising rapid review. The Think.Check.Submit. campaign, supported by a coalition of scholarly publishing and library organizations, publishes a seven-point checklist for evaluating a prospective journal before submission: whether the author or colleagues already read and recognize the journal; whether the publisher is clearly named and contactable; whether the peer-review process is described (and whether guaranteed acceptance or unusually short review times are advertised); whether the article will be indexed and preserved long-term; whether fees and the funding model are transparently stated; whether author guidelines cover licensing, copyright and conflict-of-interest policy; and whether the publisher holds current membership in bodies such as COPE and, for open-access titles, is listed in the Directory of Open Access Journals 6. The checklist advises proceeding only if most or all of these questions can be answered with confidence, which provides a final check after scope-matching and before submission.
Disclosure of conflicts of interest
Generic-medicines manuscripts frequently involve funding, consulting relationships or employment connected to originator or generic manufacturers, and reviewers and editors therefore scrutinize the conflict-of-interest disclosure section closely. The ICMJE recommendations devote a dedicated section to “Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest,” and the committee maintains a standard disclosure form, adopted by journals across the biomedical literature, so that the potentially relevant relationships of every author are reported in a consistent, comparable format rather than in free text that varies by author 7. For a generic-medicines paper, this typically entails disclosing not only direct payments but also prior consulting, advisory-board membership or equity relevant to either the generic product studied or any originator product with which it is compared.
Editorial responses to suspected ghost or guest authorship
Multi-team generic-medicines manuscripts, spanning a contract research organization, a sponsor’s regulatory affairs staff and an academic site, are precisely the setting in which the authorship disputes that COPE was established to address tend to arise. COPE’s published flowchart for suspected ghost, guest or gift authorship in a submitted manuscript instructs editors to suspend peer review first, then contact the authors directly (cross-checking current affiliations), request a formal declaration from the corresponding author that every listed author meets the journal’s authorship policy and that no qualifying contributor was omitted, and ask each individual to describe their own contribution, on the reasoning that self-reported contribution statements are more likely to be truthful than a corresponding author’s secondhand account 8. Depending on the findings of that process, the flowchart recommends either moving a “ghost” contributor into the acknowledgements section, obtaining written agreement from all authors before adding or removing a “guest” or “gift” author, or adding a missing author whose role (such as data analysis) was not credited at all 8. Resolving authorship correctly before submission avoids triggering this process after review has already begun.
Pre-submission synthesis
Before submitting a generic-medicines manuscript, authors should confirm that the stated scope of the target journal matches the sub-topic of the paper (business or regulatory, clinical, or economic) and check whether a close alternative such as GaBI Journal is more suitable; identify where comparable recent papers in the specific niche have been published; assess the target journal against a predatory-journal checklist such as Think.Check.Submit.; verify that every listed author meets all four ICMJE criteria and is prepared to complete a standard conflict-of-interest disclosure; and ensure that the ethics and conflict-of-interest statements correctly name the bodies, such as COPE and ICMJE, whose standards are cited.
Key points
Key points
The selection of a generic medicines journal requires matching the manuscript’s sub-topic to the journal’s stated editorial scope, and stating the four ICMJE authorship criteria and the name and role of COPE accurately in the submission.
Practical application
Practical application
- Match the manuscript’s sub-topic to the journal’s scope. Authors should determine whether the paper is business or regulatory, clinical or economic, and select a journal whose stated scope corresponds to that sub-topic.
- Compare the manuscript with recent comparable papers. Bibliometric trend data indicate where similar generic drug papers have been published recently.
- Verify all four ICMJE criteria for each author. Contribution, drafting or critical review, final approval and accountability should be confirmed for every listed author before submission.
- Name ethics bodies correctly. Ethics statements should use “Committee on Publication Ethics (COPE)” and “International Committee of Medical Journal Editors (ICMJE)” precisely.
Frequently asked questions
It positions itself as a business journal for the generic medicines sector, covering business development, regulatory affairs, manufacturing and marketing — not a purely clinical pharmacology venue.
Substantial contribution to the work; drafting or critically revising it; final approval of the published version; and agreement to be accountable for all aspects of the work, including resolving questions about its accuracy or integrity. All four must be met.
No. COPE assesses whether a member journal followed its own code of conduct and best-practice procedures when handling a complaint; it does not itself adjudicate the underlying scientific allegation.
References
- SAGE Publishing. Journal of Generic Medicines: Aims and Scope. read 10 October 2026. View source
- Lucas-Dominguez R, Vidal-Infer A, Alonso-Arroyo A, Navarro C, Valderrama-Zurián JC, Aleixandre-Benavent A. Patterns and trends in scientific research on generic drugs. Clinical Therapeutics. 2016;38(12):2684-2689.e1. read 10 October 2026. View source
- International Committee of Medical Journal Editors (ICMJE). Defining the Role of Authors and Contributors. read 10 October 2026. View source
- Committee on Publication Ethics (COPE). About COPE. read 10 October 2026. View source
- GaBI Journal (Generics and Biosimilars Initiative Journal). About GaBI Journal: scope, aims and editorial focus. read 10 October 2026. View source
- Think.Check.Submit. Choosing a journal: checklist for researchers evaluating a journal or publisher before submission. read 10 October 2026. View source
- International Committee of Medical Journal Editors (ICMJE). Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest. read 10 October 2026. View source
- Committee on Publication Ethics (COPE). What to do if you suspect ghost, guest or gift authorship in a submitted manuscript (flowchart). read 10 October 2026. View source
- Hernández-Vásquez A, Alarcon-Ruiz CA, Bendezu-Quispe G, Comandé D, Rosselli D. A bibliometric analysis of the global research on biosimilars. Journal of Pharmaceutical Policy and Practice. 2018;11:6. read 10 October 2026. View source
- World Association of Medical Editors (WAME). Recommendations on chatbots and generative artificial intelligence in relation to scholarly publications, including its application of ICMJE authorship criteria. read 10 October 2026. View source
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics. Pubrica. https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/
Pubrica Academy. “Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics.” Pubrica, 10 Oct. 2026, pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/.
Pubrica Academy (2026) Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics. Pubrica. Available at: https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/ (Accessed: 15 October 2026).
Pubrica Academy. “Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics.” Pubrica. October 10, 2026. https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/
Pubrica Academy, ‘Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/> accessed 15 October 2026.
Pubrica Academy. Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/
Pubrica Academy, “Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/
@misc{/la_select_generic_medicines_journals_submit_manuscript_2026,
author = {{Pubrica Academy}},
title = {Selecting Generic Medicines Journals for Manuscript Submission: Scope, Authorship and Publication Ethics},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/manuscript-writing/how-to-select-generic-medicines-journals-to-submit-the-manuscript/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Generic medicines submission checklist
A checklist to complete before submission to a generic-medicines journal.
[ ] Manuscript sub-topic matched to journal's stated scope [ ] Comparable recent papers' publication venues checked [ ] Every author verified against all four ICMJE criteria [ ] Ethics statement names ICMJE and COPE correctly [ ] Conflict-of-interest and funding disclosures complete
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s manuscript support team identifies appropriate specialty journals for generic medicines manuscripts and verifies authorship and ethics statements against ICMJE and COPE standards before submission.